An Extension of an Interventional Study to Assess the Effect of Expanded Dialysis (HDx-Theranova) on Patient Reported Symptoms Using London Evaluation of Illness (LEVIL)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness LEVIL, an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Conventional thrice weekly HD schedule

• Must be on chronic hemodialysis for at least 3 months

• Age ≥18 years

• Willing and able to give informed consent

Locations
Other Locations
Canada
Victoria Hospital, London Health Sciences Centre
RECRUITING
London
Westmount Kidney Care Centre
RECRUITING
London
Contact Information
Primary
Christopher McIntyre, MBBS DM
Christopher.McIntyre@lhsc.on.ca
5196858500
Backup
Jarrin Penny, PHD RN CNeph
jarrin.penny@lhsc.on.ca
519-685-8500
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100
Treatments
Experimental: Patients receiving Hemodialysis
A group of hemodialysis patients will be receiving the Theranova dialyzer during their regular scheduled dialysis sessions to remove larger middle molecules.
Related Therapeutic Areas
Sponsors
Leads: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: Baxter Healthcare Corporation

This content was sourced from clinicaltrials.gov